As a wave of patent expirations encroaches upon many of the world’s top drugmakers, companies will need to be diligent in ...
GSK Pharmaceuticals India focuses on affordable general medicine access amidst premiumisation trend, discussed by managing ...
Third quarter results highlight strong operational performance across key value drivers: YUPELRI® (revefenacin) net sales of $62.2 million, recognized by Viatris ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback